Cancer cells missing MTAP rely on MAT2A to make enough SAM to both counteract a natural inhibitor (MTA) and produce DNA building blocks; blocking MAT2A starves them of both, which normal cells can survive without.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether the dual-dependency model predicts clinical response to MAT2A inhibitors across diverse MTAP-deleted tumor types.
A systematic review and meta-analysis of all clinical trials using MAT2A inhibitors in MTAP-deleted cancers, correlating tumor SAM levels, MTA concentrations, and PRMT5 methylation signatures with objective response rates and survival outcomes across >10 trials.
Whether dual-pathway inhibition (MAT2A + PRMT5) improves outcomes compared to single-agent inhibition in MTAP-deleted tumors.
A double-blind RCT of 200 patients with MTAP-deleted advanced solid tumors randomized to IDE397 alone, PRMT5 inhibitor alone, combination, or placebo, with primary endpoint of progression-free survival and biomarker analysis of SAM, MTA, and PRMT5 substrates pre- and post-treatment.
Whether patients with higher baseline MTA and lower SAM levels respond better to MAT2A inhibitors.
A prospective cohort of 150 patients with MTAP-deleted tumors treated with IDE397, measuring pre-treatment tumor MTA and SAM levels via mass spectrometry and correlating these with response duration and tumor shrinkage.
Whether non-responders to MAT2A inhibitors have compensatory metabolic pathways that bypass SAM dependency.
A matched case-control study comparing 40 responders and 40 non-responders to IDE397, analyzing transcriptomic and metabolomic profiles for upregulated salvage pathways (e.g., adenine synthesis, polyamine metabolism) in non-responders.
The prevalence of dual metabolic vulnerabilities (high MTA + low SAM) in MTAP-deleted tumors across tumor types.
A cross-sectional analysis of 500 MTAP-deleted tumor samples from multiple cancer types, measuring MTA and SAM concentrations and correlating with MTAP deletion status and tumor grade.